scholarly journals Clinical pharmacological particular qualities of original ibuprofen different forms in treatment of diseases manifesting by pain

2021 ◽  
Vol 23 (2) ◽  
pp. 175-180
Author(s):  
Mikhail V. Pchelintsev ◽  
Keyword(s):  
Clinical Trials ◽  
Present Article ◽  
Randomized Clinical Trials ◽  
Analgesic Efficacy ◽  
Special Consideration ◽  
Nociceptive Pain ◽  
Efficacy And Safety ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

In the present article, the role of non-steroidal anti-inflammatory drugs in treatment of different diseases manifesting by nociceptive pain is viewed. Special consideration is given to Ibuprofen, which is very often used as a non-prescription analgesic and/or anti-pyretic agent. Using the examples of randomized clinical trials and meta-analyzes carried on their basis, a high comparative analgesic efficacy and safety of use of original ibuprofen, Nurofen®, in different pharmaceutical forms in particular in a form of rapidly absorbed tablets and in combination with paracetamol.

scholarly journals Clinical Outcomes of Aspirin Interaction with Other Non-Steroidal Anti-Inflammatory Drugs: A Systematic Review

2018 ◽  
Vol 21 (1s) ◽  
pp. 48s-73s ◽  
Author(s):  
Zuhair Alqahtani ◽  
Fakhreddin Jamali
Keyword(s):  
Clinical Trials ◽  
Platelet Aggregation ◽  
Clinical Outcomes ◽  
Randomized Clinical Trials ◽  
Ex Vivo ◽  
Biologically Active ◽  
Cardioprotective Effect ◽  
Inflammatory Drugs ◽  
Anti Inflammatory ◽  
Aggregation Level

Purpose: Concomitant use of some non-Aspirin nonsteroidal anti-inflammatory drugs (NANSAIDs) reduces the extent of platelet aggregation of Aspirin (acetylsalicylic acid). This is while many observational studies and clinical trials suggest that Aspirin reduces cardiovascular (CV) risk attributed to the use of NANSAIDs. Thus, the therapeutic outcome of the interaction needs to be assessed. Methods: We searched various databases up to October 2017 for molecular interaction studies between the drugs and long-term clinical outcomes based on randomized clinical trials and epidemiological observations that reported the effect estimates of CV risks (OR, RR or HR; 95% CI) of the interacting drugs alone or in combinations. Comparisons were made between outcomes after Aspirin alone, NANSAIDs alone and Aspirin with naproxen, ibuprofen, celecoxib, meloxicam, diclofenac or rofecoxib. Results: In total, 32 eligible studies (20 molecular interactions studies and 12 observational trials) were found. Conflicting in vitro/in vivo/ex vivo platelet aggregation data were found for ibuprofen, naproxen and celecoxib. Nevertheless, for naproxen, the interaction at the aggregation level did not amount to a loss of cardioprotective effects of Aspirin. Similarly, for ibuprofen, the results overwhelmingly suggest no negative clinical CV outcomes following the combination therapy. Meloxicam and rofecoxib neither interacted with Aspirin at the level of platelet aggregation nor altered clinical outcomes. The clinical outcomes data for celecoxib and diclofenac are in conflict. Conclusion: Aspirin appears to maintain its cardioprotective effect in the presence of naproxen, ibuprofen, meloxicam and rofecoxib. The limited available data suggest that the effect of interaction at the platelet aggregation level may dissipate shortly, or the reduced platelet aggregation yielded by the interaction may be sufficient for cardioprotection; i.e., no need for near complete aggregation. In addition, cardioprotective effect of Aspirin, despite reduced platelet aggregation caused by NANSAIDs, may be through its involvement in other mechanisms such as the renin-angiotensin system and/or metabolism of arachidonic acid to biologically active compounds mediated by cytochrome P450. This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For Readers”) may comment by clicking on ABSTRACT on the issue’s contents page.

Pharmacotherapy of Juvenile Idiopathic Arthritis

2008 ◽  
Vol 22 (1) ◽  
pp. 17-28 ◽  
Author(s):  
Edward A. Bell
Keyword(s):  
Clinical Trials ◽  
Juvenile Idiopathic Arthritis ◽  
Initial Therapy ◽  
Biologic Agents ◽  
Rheumatic Disorder ◽  
Inflammatory Drugs ◽  
Anti Inflammatory ◽  
Therapy Methotrexate

Juvenile idiopathic arthritis is the most common rheumatic disorder of childhood, and is defined as arthritis beginning prior to the age of 16 years, lasting more than 6 weeks, with an unknown cause. Seven subtypes of juvenile idiopathic arthritis have recently been categorized and named. These subtypes differ broadly in the number of affected joints and the presence of systemic illness. Although many children with juvenile idiopathic arthritis may achieve remission prior to entering adulthood, many others will continue to have debilitating disease into adulthood. Pharmacotherapy plays a major role in the treatment of juvenile idiopathic arthritis. Nonsteroidal anti-inflammatory drugs and corticosteroids can be beneficial for many children and are used as initial therapy. Methotrexate may offer benefits to children unresponsive to these initial agents. Studies evaluating the use of several biologic agents and immunosuppressants have recently been published, and the role of these drugs for children with juvenile idiopathic arthritis is being assessed. Major clinical trials and pediatric implications are reviewed.

scholarly journals Brazilian recommendations for the use of nonsteroidal anti-inflammatory drugs in patients with axial spondyloarthritis

2021 ◽  
Vol 61 (1) ◽  
Author(s):  
Ricardo da Cruz Lage ◽  
Claudia Diniz Lopes Marques ◽  
Thauana Luiza Oliveira ◽  
Gustavo Gomes Resende ◽  
Charles Lubianca Kohem ◽  
...  
Keyword(s):  
Randomized Clinical Trials ◽  
Axial Spondyloarthritis ◽  
Meta Analysis ◽  
Evaluation Methodology ◽  
Assessment Development ◽  
Brazilian Society ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

AbstractSpondyloarthritis (SpA) is a group of chronic inflammatory systemic diseases characterized by axial and/or peripheral joints inflammation, as well as extra-articular manifestations. Over some decades, nonsteroidal anti-inflammatory drugs (NSAIDs) have been the basis for the pharmacological treatment of patients with axial spondyloarthritis (axSpA). However, the emergence of the immunobiologic agents brought up the discussion about the role of NSAIDs in the management of these patients. The objective of this guideline is to provide recommendations for the use of NSAIDs for the treatment of axSpA. A panel of experts from the Brazilian Society of Rheumatology conducted a systematic review and meta-analysis of randomized clinical trials for 15 predefined questions. The Grading of Recommendations, Assessment, Development and Evaluation methodology to assess the quality of evidence and formulate recommendations were used, and at least 70% agreement of the voting panel was needed. Fourteen recommendations for the use of NSAIDs in the treatment of patients with axSpA were elaborated. The purpose of these recommendations is to support clinicians’ decision making, without taking out his/her autonomy when prescribing for an individual patient.

Government Initiatives in Autism Clinical Trials

CNS Spectrums ◽  
2004 ◽  
Vol 9 (1) ◽  
pp. 66-70 ◽  
Author(s):  
Benedetto Vitiello ◽  
Ann Wagner
Keyword(s):  
Clinical Trials ◽  
Randomized Clinical Trials ◽  
National Institutes Of Health ◽  
Efficacy And Safety ◽  
Autism Research ◽  
Autism Treatment ◽  
Treatment Research ◽  
Health Relevance ◽  
Valid Information

ABSTRACTRandomized clinical trials remain the most valid method of testing the efficacy and safety of treatments. While efforts to elucidate the genetic and neurodevelopmental bases of autism are underway, clinicians and families are in need of scientifically valid information on how to best treat patients with autism. The effectiveness of many interventions currently used in communities has not been adequately tested. Given the high public health relevance of autism treatment research and the low interest of the pharmaceutical industry in autism, the role of the National Institutes of Health in supporting this research is paramount. Among recently launched initiatives in autism clinical trials, there are the Research Units on Pediatric Psychopharmacology Autism Network and the network of centers for Studies to Advance Autism Research and Treatment. These and other government activities in the area of autism clinical trials are here briefly reviewed.

scholarly journals Alpha-1 Antitrypsin for COVID-19 Treatment: Dual Role in Antiviral Infection and Anti-Inflammation

2020 ◽  
Vol 11 ◽  
Author(s):  
Chengliang Yang ◽  
Shaf Keshavjee ◽  
Mingyao Liu
Keyword(s):  
Clinical Trials ◽  
Lung Injury ◽  
Dual Role ◽  
Host Cells ◽  
Inflammatory Drugs ◽  
Anti Inflammatory ◽  
Alpha 1 Antitrypsin ◽  
Transmembrane Serine Protease ◽  
Anti Inflammation

Many drugs have been approved for clinical trials for the treatment of COVID-19 disease, focusing on either antiviral or anti-inflammatory approaches. Combining antiviral and anti-inflammatory drugs or therapies together may be more effective. Human alpha-1 antitrypsin (A1AT) is a blood circulating glycoprotein that is best known as a protease inhibitor. It has been used to treat emphysema patients with A1AT deficiency for decades. We and others have demonstrated its role in reducing acute lung injury by inhibiting inflammation, cell death, coagulation, and neutrophil elastase activation. Recently, A1AT has been found to inhibit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection by inhibiting transmembrane serine protease 2 (TMPRSS2), a protease involved in the entry of SARS-CoV-2 into host cells. This dual role of both antiviral infection and anti-inflammation makes A1AT a unique and excellent candidate for COVID-19 treatment. Three clinical trials of A1AT for COVID-19 treatment have recently been approved in several countries. It is important to determine whether A1AT can prevent the progress from moderate to severe lung injury and eventually to be used to treat COVID-19 patients with acute respiratory distress syndrome.

scholarly journals Acute coronary syndrome: how to reduce the residual inflammatory risk?

2020 ◽  
Vol 25 (2) ◽  
pp. 113-118
Author(s):  
V. I. Shalnev
Keyword(s):  
Coronary Artery Disease ◽  
Clinical Trials ◽  
Acute Coronary Syndrome ◽  
Coronary Artery ◽  
Randomized Clinical Trials ◽  
Clinical Course ◽  
Coronary Syndrome ◽  
Inflammatory Drugs ◽  
Artery Disease

Inflammatory mediators play an important role in the pathogenesis of acute coronary syndrome (ACS). The results of experimental and randomized clinical trials on the role of various inflammation inhibitors in the treatment of coronary artery disease (CAD), in particular CANTOS and COLCOT, mark a new stage that can significantly change the clinical course and outcomes of the disease. We analyze our own experience in studying this problem. There are much prospects for the use of immunomodulatory and anti-inflammatory drugs reducing the residual inflammatory risk, but additional studies are needed to determine their role in the treatment of CAD.

Sign in / Sign up

Export Citation Format

Share Document